Riskpilot← Back to searchSign inGet full accessEvolan Pharma AB
ABActiveOrg 5567189781Svärdvägen 19Wholesale of pharmaceutical and medical goods · NACE 4646Est. 200630 employees
Revenue 2025
SEK 1,2B
+18% vs 2024
EBITDA margin
47.8%
+37% vs 2024
Equity ratio
84.1%
Financial strength
Net profit 2025
SEK 527M
+139% vs 2024
| Revenue | SEK 1,2B | +18% |
| EBITDA | SEK 567,7M | +37% |
| Net profit | SEK 527M | +139% |
| Total assets | SEK 1,5B | +22% |
| Equity | SEK 1,2B | +70% |
| Employees | 30 | — |
Legal name
Evolan Pharma AB
Org number
5567189781
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
29 december 2006
Share capital
SEK 100 000
Employees
30 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas ensam av Karroum, Said Richard
Company purpose
Bolaget ska tillverka och försälja läkemedel, medicintekniska produkter och naturläkemedel samt därmed förenlig verksamhet.
Address
Svärdvägen 19
Phone
+46854496030
Email
richard.karroum@evolan.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 327 401 | 440 426 | 543 412 | 668 681 | 736 919 | 948 637 | 1 002 613 | 1 186 466 |
| Staff expenses | — | — | — | — | — | — | — | — | — | — | −38 216 |
| EBITDA | 32 358 | 33 066 | 54 332 | 89 206 | 147 121 | 190 285 | 265 027 | 306 627 | 400 047 | 414 457 | 567 678 |
| Depreciation & amort. | −1 901 | −3 268 | −21 642 | −40 410 | −46 087 | −66 857 | −71 463 | −76 884 | −105 747 | −80 681 | −110 036 |
| EBIT | 30 457 | 29 798 | 32 690 | 48 796 | 101 034 | 123 428 | 193 564 | 229 743 | 294 300 | 333 776 | 457 641 |
| Net financials | 179 | 461 | −1 389 | −8 845 | −5 666 | −1 407 | 1 365 | 4 135 | −6 768 | −3 610 | −642 |
| Profit before tax | 24 205 | 19 963 | 874 | 38 814 | 73 156 | 100 211 | 147 175 | 184 836 | 217 530 | 290 528 | 665 847 |
| Tax | −5 209 | −4 406 | −41 | −8 903 | −15 772 | −22 281 | −30 230 | −35 497 | −58 825 | −69 614 | −138 885 |
| Net profit | 18 996 | 15 557 | 833 | 29 911 | 57 384 | 77 930 | 116 945 | 149 339 | 158 705 | 220 914 | 526 962 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 73 069 | 127 715 | 298 329 | 300 195 | 391 725 | 420 577 | 552 285 | 863 471 | 1 017 471 | 1 211 124 | 1 482 382 |
| Equity | 19 136 | 17 404 | 3 672 | 35 447 | 80 158 | 149 588 | 250 533 | 373 290 | 522 163 | 732 076 | 1 246 038 |
| Long-term debt | 20 907 | 57 376 | 135 965 | 83 326 | 72 377 | 20 992 | 985 | 78 734 | 0 | 0 | — |
| Short-term debt | 23 883 | 32 044 | 108 801 | 131 931 | 162 142 | 150 437 | 153 067 | 213 748 | 227 609 | 211 348 | 193 644 |
| Total debt | 44 790 | 89 420 | 244 766 | 215 257 | 234 519 | 171 429 | 154 052 | 292 482 | 227 609 | 211 348 | 193 644 |
EBITDA margin
47.8%
This company
15.8%
Market median
+203% vs market
20152025
Equity ratio
84.1%
This company
38.2%
Market median
+120% vs market
20152025
Return on equity
42.3%
This company
18.4%
Market median
+130% vs market
20152025
Net profit margin
44.4%
This company
8.1%
Market median
+448% vs market
20152025
Asset turnover
0.80×
This company
1.12×
Market median
-29% vs market
20152025
Debt / equity
0.19×
This company
0.62×
Market median
+69% vs market
20152025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
RN Chief Auditor | Chief Auditor | 2021 | — | — |
PM Chief Auditor | Chief Auditor | 2025 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2024 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Chairman | 2021 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Rosemed Holding AB | Company | 100.0% | 100.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Rosemed Holding AB
Evolan Pharma AB Board members of Evolan Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Rolf Nicklas Kullberg | Chief Auditor | 0 companies |
| Peter Magnus Kangas | Chief Auditor | 0 companies |
| Said Richard Karroum | Chairman | 0 companies |
| Ulrika Elisabeth Marie Håkansson | Board of Directors | 0 companies |
| Francois Alexander Karroum | Deputy Board Member | 0 companies |
| Anders Leif Håkansson | Chairman | 0 companies |
| Sven Fredrik Syrén Engström | Board of Directors | 0 companies |